Memantine Treatment in Alcohol Dementia: Rapid PET Changes and Clinical Course

Preuss, Ulrich W.; Bahlmann, Miriam; Bartenstein, Peter; Schütz, Christian; Soyka, Michael

doi:10.1159/000052094

Cited by 9 publications

(12 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Statistically significant changes were observed in MMSE scores of word list recall (p<0.05), word list recognition (p<0.05), time recognition (p<0.05), ability to draw an interlocking pentagon (p<0.05) and in the total MMSE score (p<0.01). This result was similar to that of a previous study reported by Preuss et al (2001) who reported the improvement of MMSE scores together with verbal fluency, word list recall and drawing in the CERAD-K after a 5-wk period of memantine treatment. In the present study, CERAD-K verbal fluency was not significantly improved.…”

Section: Discussionsupporting

confidence: 92%

“…Global cognition measured by the MMSE improved by 2 points (from 17.21 to 19.59) in the present study. This result might be a relatively small improvement when compared to the finding of Preuss et al (2001) that reported a 4-point increase in the MMSE after 5-wk treatment with memantine for patients with ARD.…”

Section: Discussioncontrasting

confidence: 66%

“…However, the study of pharmacological treatment for ARD is extremely rare. To our knowledge, there exist only three cases on treatment for ARD, each of which introduced improvements through prescription of memantine (Preuss et al, 2001), donepezil , and rivastigmine (Gibson and Barnaby, 2003).…”

Section: Discussionmentioning

confidence: 99%

“…Regarding memantine, there was a report that mentioned its efficacy in 16 demented patients with Wernicke-Korsakoff syndrome (Rustembegovic et al, 2003), and a case report of ARD that showed evidence of improvement on the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) test and FDG-PET scores with memantine treatment (Preuss et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The effect of 12-week open-label memantine treatment on cognitive function improvement in patients with alcohol-related dementia

Cheon

Park²,

Joe

et al. 2008

Int. J. Neuropsychopharm.

View full text Add to dashboard Cite

There is compelling evidence that alcohol-induced neurotoxicity is related to glutamate excitotoxicity. It was hypothesized that the low-affinity NMDA receptor antagonist memantine would improve the cognitive function of patients with alcoholic dementia. The aim of this study was to test this hypothesis and to evaluate the effect of memantine on the cognitive improvement of patients with alcohol-related dementia (ARD). The study was designed as a 12-wk open-label study investigating the efficacy of 20 mg memantine, a low-affinity NMDA receptor antagonist, as a treatment for cognitive and behavioural problems in 19 patients with probable ARD according to the criteria for ARD proposed by Oslin and colleagues. The CERAD-K (Consortium to Establish a Registry for Alzheimer's Disease - Korean version) and several clinical assessment scales were completed before and after the 12-wk memantine treatment period. Significant improvements in the mean scores from baseline to final assessment were observed in the Global Deterioration Scale (p<0.05), Brief Psychiatric Rating Scale (p<0.01), Geriatric Quality of Life - Dementia scale (p<0.01) and Neuropsychiatric Inventory (p<0.01) at the end of week 12. The CERAD-K subscales of word list recall (p<0.05), word list recognition (p<0.05), time orientation (p<0.01), drawing an interlocking pentagon (p<0.05), and the total MMSE-K (Mini Mental State Examination - Korean version) scores (p<0.01) of the patients all showed significant improvement following the memantine trial. In this open-label study, patients with ARD treated with 20 mg/d memantine for 12 wk showed improvement on global cognition, quality of life and behavioural symptoms. The result of this study suggests the possible usefulness of memantine for the treatment of ARD. As this was an open-label study, the possibility that participants improved cognitively on their own due to protracted abstinence from alcohol cannot be discounted.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussioncontrasting

confidence: 66%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The effect of 12-week open-label memantine treatment on cognitive function improvement in patients with alcohol-related dementia

Cheon

Park²,

Joe

et al. 2008

Int. J. Neuropsychopharm.

View full text Add to dashboard Cite

show abstract

“…Cerebral hypometabolism associated with cognitive impairment after TBI has been demonstrated diffuse or focal lesions in the frontal, parietal, temporal, and occipital cortices [26,27]. There are a few preliminary studies [22,28] demonstrating a enhancing effect of memantine on the frontal cerebral metabolism in schizophrenia [22] and alcohol-induced dementia [28], but not much is known about the underlying mechanism of memantine's effect on cognition and cerebral metabolism in TBI. The current study was the first to investigate the changes in cerebral glucose metabolism following memantine therapy in posttraumatic cognitive impairment.…”

Section: Discussionmentioning

confidence: 99%

Changes in cerebral glucose metabolism in patients with posttraumatic cognitive impairment after memantine therapy: a preliminary study

Kim

Shin

2010

Ann Nucl Med

View full text Add to dashboard Cite

show abstract

Alterations of regional cerebral blood flow after NMDA receptor antagonist administration in patients with alcohol‐related dementia

Chon

Jeong

et al. 2017

Int J Imaging Syst Tech

View full text Add to dashboard Cite

Although N‐methyl‐d‐aspartate (NMDA) receptor antagonists may have beneficial influences on cognition in patients with alcohol‐related dementia (ARD), their effects on regional cerebral blood flow (rCBF) remain unknown. This study evaluated changes in rCBF in ARD patients after administration of NMDA receptor antagonist for 12 weeks using technetium‐99m ethyl cysteinate dimer (Tc‐99m ECD) single‐photon emission computed tomography (SPECT). Twenty‐eight ARD patients were administered memantine for 12 weeks and underwent clinical evaluations and brain SPECT scans at baseline and follow‐up. Whole‐brain changes in perfusion were examined on a voxel‐by‐voxel basis. At follow‐up, the patients showed reduced rCBF in the left medial frontal gyrus, left cingulate gyrus, left claustrum, right brainstem, left superior temporal gyrus, bilateral fusiform gyrus, and left cerebellum. On the other hand, increased rCBF was found in the bilateral uncus, left parahippocampal gyrus, bilateral superior frontal gyrus, right inferior parietal lobule, left cuneus, and left superior temporal gyrus. Perfusion increases in various brain areas including the superior frontal, parahippocampal, and inferior parietal areas, which may play important roles in the pathophysiology of ARD, suggest potential benefits of NMDA receptor antagonists on brain functions in patients with ARD.

show abstract

Memantine Treatment in Alcohol Dementia: Rapid PET Changes and Clinical Course

Cited by 9 publications

References 5 publications

The effect of 12-week open-label memantine treatment on cognitive function improvement in patients with alcohol-related dementia

The effect of 12-week open-label memantine treatment on cognitive function improvement in patients with alcohol-related dementia

Changes in cerebral glucose metabolism in patients with posttraumatic cognitive impairment after memantine therapy: a preliminary study

Alterations of regional cerebral blood flow after NMDA receptor antagonist administration in patients with alcohol‐related dementia

Contact Info

Product

Resources

About